Recent milestones in the evolution of Standard of Care treatment in advanced urothelial carcinoma (ID 6015)
Sequencing anticancer agents across lines of therapy in advanced urothelial carcinoma (ID 6016)
Learnings from real-world data to optimize treatment in advanced urothelial carcinoma (ID 6017)
Mini-debates on ‘hot topics’ in advanced urothelial carcinoma (ID 6018)
Closing remarks (ID 6019)
